EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

By Crafter Claire   Vincent John P.   Tang Eric   Dudley Phillippa   James Neil H.   Klinowska Teresa   Davies Barry R.  

International Journal of Oncology, Vol. 47, Iss. 2, 2015-08 ,pp. : 446-454

Spandidos Publications

Access to resources Recommend Favorite

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

By Morrison Gladys   Fu Xiaoyong   Shea Martin   Nanda Sarmistha   Giuliano Mario   Wang Tao   Klinowska Teresa   Osborne C.   Rimawi Mothaffar   Schiff Rachel  

Breast Cancer Research and Treatment, Vol. 144, Iss. 2, 2014-04 ,pp. : 263-272

Springer Publishing Company

Access to resources Recommend Favorite

Cytotoxicity of Cord Blood Derived Her2/ neu -specific Cytotoxic T Lymphocytes against Human Breast Cancer in vitro and in vivo

By Wang Peng   Munger Corey M.   Joshi Avadhut D.   Pirruccello Samuel J.   Joshi Shantaram S.  

Breast Cancer Research and Treatment, Vol. 83, Iss. 1, 2004-01 ,pp. : 15-23

Springer Publishing Company

Access to resources Recommend Favorite

Recent Advances in the Development of P-gp Inhibitors

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 4, 2009-05 ,pp. : 415-436

Bentham Science Publishers

Access to resources Recommend Favorite